News

Cypralis have been granted an Innovate UK early stage award to develop cyclophilin D inhibitors.

Pathological Tau kills excitatory neurons on entorhinal cortex leading to misalignment of grid fields and deterioration of spatial cognition.

University of California San Francisco will partner with AbbVie, Amgen and Bristol Myers Squibb to analyse at least 500 tumour samples for immunologically relevant characteristics.

Technique enables rapid delivery of RNA to treat colon inflammation.

The world's largest sickle stem cell disease library will contain a diverse range of samples that can be used to study the disease and develop therapeutics.

Cancerous cells often delete genes that suppress tumor formation, often these genes deletions extend into neighboring genes, this is known as "collateral lethality".

A team of scientists at The Scripps Research Institute have developed a new method that enhances the discovery of new drugs and the study of proteins. The new method enables researchers to quickly find small molecules that bind to hundreds of thousands of proteins in their native cellular environment.

OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors

Eli Lilly announce purchase of CoLucid pharmaceuticals for $960m. They also acquire their late stage migraine treatment, lasmiditan.

The collaboration will grant Taiho access to X-Chem’s DEX™ technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules.